Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Science

Rudolf Jaenisch at MIT to Speak at Stem Cell Summit – Apr 2013 in Cambridge, MA


Print article Print article
2014-02-28 07:48:57 - Rudolf Jaenisch, Founding Member of the Whitehead Institute & Professor of Biology at MIT to Give a Plenary Keynote Presentation on “iPS Cell Technology, Gene Editing and Disease Research” at the Stem Cell Summit (Apr 23-25, 2014 in Cambridge, MA)

Rudolf Jaenisch, founding member of the Whitehead Institute and professor of biology at the Massachusetts Institute of Technology will give a plenary keynote presentation on, “iPS Cell Technology, Gene Editing and Disease Research” the Stem Cell Summit 2014 to be held on April 23-25, 2014 in Cambridge, MA.

The recent demonstration of in vitro reprogramming using transduction of 4 transcription factors by Yamanaka and colleagues represents a major advance in the field. However, major questions regarding the mechanism of in vitro reprogramming need to be understood and will be one focus of the talk. A major impediment in realizing the potential of ES and iPS cells to study human diseases is the inefficiency of gene targeting. Methods based on Zn

finger or TALEN mediated genome editing have allowed to overcome the inefficiency of homologous recombination in human pluripotent cells. Using this genome editing approaches we have established efficient protocols to target expressed and silent genes in human ES and iPS cells. The most recent advance comes from the use of the CRISPR/Cas9 system to engineer ES cells and mice. This technology allows the simultaneous editing of multiple genes and will facilitate establishing relevant models to study human disease. This technology was used to generate isogenic pairs of cells that differ exclusively at a disease causing mutation. The talk will describe the use or isogenic pairs of mutant and control iPS cells to establish in vitro systems for the study of diseases such as Parkinson’s and Rett syndrome.

Rudolf Jaenisch is a pioneer of transgenic science, in which an animal’s genetic makeup is altered. He has focused on creating transgenic mice to study cancer and neurological diseases. Jaenisch’s first breakthrough occurred in 1974 when he and Beatrice Mintz showed that foreign DNA could be integrated into the DNA of early mouse embryos. They injected retrovirus into early mouse embryos and showed that leukemia DNA sequences had integrated the mouse genome and also to its offspring. These mice were the first transgenic mammals in history.

Dr. Jaenisch will join other top experts from academia, industry and government to discuss recent developments in stem cell research. Experts will discuss pre-clinical and clinical trials of stem cell therapy, regenerative medicine, tissue engineering, cancer stem cells, stem cell reprogramming, new paradigms for drug discovery/cell therapy and regulatory policies. Experts will also discuss other important stem cell issues such business opportunities, challenges in commercialization and the potential strategies for overcoming these challenges. What categories of companies are currently commercially viable? How are they being funded? What kind of strategic relationships are available within the industry?

In its 11th year, the Stem Cell Summit 2014 includes two parallel conferences including joint sessions. This summit provides cutting-edge information on developments in all areas of stem cell research including the biology, medicine, applications, regulations, and commercialization of stem cells.

For more information, please visit www.gtcbio.com/stemcellsummit


Contact Information:
GTC

635 W. Foothill Blvd. Monrovia, CA 91016

Contact Person:
Kristen Starkey

Phone: 6262566405
email: email

Web: www.gtcbio.com



Author:
Rania hafez
e-mail
Web: www.gtcbio.com
Phone: 626-256-6405

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com